Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM TETRADECYL SULFATE vs TALC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.
Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.
Treatment of uncomplicated spider veins (telangiectasias) and reticular veins,Treatment of small varicose veins (off-label for larger varicose veins)
Pleurodesis for malignant pleural effusion,Pleurodesis for recurrent pneumothorax
1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.
Intrapleural administration: 5 g mixed with 250 m L normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.
Approximately 2.5 hours (range 1.5–4 hours) in patients with normal renal function. Clinical context: prolonged in renal impairment, requiring dose adjustment.
Not applicable; talc is a non-absorbable material. No systemic half-life exists; local persistence in pleural space can be months to years.
Not extensively metabolized; primarily eliminated unchanged by the kidneys.
Not metabolized; inert substance. Cleared by lymphatic drainage and phagocytosis by macrophages.
Primarily renal; approximately 95% of the dose is excreted unchanged in urine within 24 hours. Minor biliary/fecal elimination (<5%).
Talc is not absorbed systemically; elimination is primarily via fecal excretion of the unabsorbed material. In cases of pleural administration, talc particles are cleared by lymphatic drainage and may be phagocytized by macrophages; no significant renal or biliary excretion occurs.
Approximately 50% bound to plasma proteins (albumin and globulins).
Not applicable; talc does not bind to plasma proteins as it is not systemically absorbed.
0.2–0.3 L/kg, indicating distribution primarily within extracellular fluid and plasma volume.
Not applicable; talc remains at site of administration (pleural space, lungs) or in GI tract; no systemic distribution.
Intravenous: 100% (direct intravascular administration). Oral: negligible due to extensive degradation and poor absorption.
Oral: negligible (<0.1%); inhalation: minimal systemic absorption; intrapleural: not systemically available.
No dose adjustment required for renal impairment.
No dose adjustment required; talc is not significantly renally eliminated.
Use with caution in Child-Pugh class C; no specific dose adjustment defined.
No dose adjustment required.
0.1-0.3 m L of 1% solution per injection, repeated as needed; maximum 5 m L per session.
Not established; safety and efficacy in children have not been determined.
No specific adjustment; use lowest effective dose due to potential increased sensitivity.
No specific dose adjustment; use with caution due to potential comorbidities and reduced pulmonary reserve.
None.
None
Anaphylactic shock and severe allergic reactions have been reported.,Intra-arterial injection can cause severe necrosis or ischemia.,Extravasation may cause pain and tissue necrosis.,Use caution in patients with underlying arterial disease or hypercoagulable states.,Thromboembolic events including deep vein thrombosis and pulmonary embolism have been reported.
Risk of acute respiratory distress syndrome (ARDS) and pneumonitis due to systemic absorption,Hypersensitivity reactions including anaphylaxis,Fever and chest pain common post-procedure,Do not use in patients with extensive pleural fibrosis or trapped lung
Known hypersensitivity to sodium tetradecyl sulfate or any component of the formulation,Acute thromboembolic disease,Severe peripheral arterial disease,Valvular incompetence of the deep venous system,Uncontrolled systemic disease (e.g., diabetes, thyroid disorders),Local infection or inflammation at the injection site
Hypersensitivity to talc,Uncontrolled infection at the site of administration,Bronchopleural fistula,Pregnancy (relative)
No specific food interactions have been reported with sodium tetradecyl sulfate. However, maintaining adequate hydration is recommended. Avoid excessive alcohol intake, as it may exacerbate venous insufficiency.
No known food interactions with intrapleural talc administration.
Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack of safety data, especially in the first trimester. Theoretical risk of placental transfer is low due to high molecular weight and local administration. No reported fetal anomalies.
No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester.
No data on excretion into human milk. M/P ratio unknown. Due to local administration and rapid metabolism, systemic exposure is minimal. Caution advised; consider discontinuing breastfeeding or avoiding use in lactating women.
Talc is not absorbed systemically; topical use considered safe during breastfeeding. No M/P ratio available as systemic levels are negligible.
No specific dose adjustments recommended. Use only if clearly needed, with smallest effective volume and concentration. Physiological changes in pregnancy (increased plasma volume, altered coagulation) may affect response but no pharmacokinetic data exist.
No dose adjustment required for topical or perineal use; systemic levels negligible.
Sodium tetradecyl sulfate is a sclerosing agent used for the treatment of varicose veins and telangiectasias. It works by causing endothelial damage and subsequent fibrosis of the vein. Use with caution in patients with a history of deep vein thrombosis, pulmonary embolism, or hypercoagulable states. Allergic reactions, including anaphylaxis, have been reported; a test dose is recommended. Avoid extravasation as it may cause tissue necrosis. Compression stockings should be applied post-injection to enhance efficacy and reduce complications.
Talc is used for pleurodesis in malignant pleural effusions. Administer as intrapleural slurry via chest tube; premedicate with lidocaine to reduce pain. Monitor for fever, chest pain, and respiratory distress. Contraindicated in patients with known talc sensitivity or active infection.
This medication is injected directly into your varicose veins to cause them to scar and close.,You may experience temporary bruising, pain, or redness at the injection site.,It is normal for the treated veins to feel hard and lumpy for a few weeks after treatment.,You will need to wear compression stockings for several days to weeks as directed by your healthcare provider.,Avoid sun exposure to the treated area until bruising resolves to reduce the risk of hyperpigmentation.,Seek immediate medical attention if you experience signs of an allergic reaction, chest pain, or difficulty breathing.,Do not discontinue prescribed blood thinners unless instructed by your doctor, as the risk of bleeding may be increased.
Talc is used to prevent fluid buildup in the chest cavity by causing the lung to stick to the chest wall.,You may experience chest pain, fever, or shortness of breath after the procedure.,Report any worsening pain, difficulty breathing, or signs of infection such as chills or fever.,This procedure is not a cure for the underlying cancer but helps manage symptoms.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM TETRADECYL SULFATE vs TALC, answered by our medical review team.
SODIUM TETRADECYL SULFATE is a Sclerosing Agent that works by Sodium tetradecyl sulfate is a synthetic anionic surfactant that acts as a sclerosing agent. It works by causing endothelial damage and inflammation of the venous wall, leading to fibrosis and occlusion of the injected vein.. TALC is a Sclerosing agent that works by Talc (magnesium silicate) induces pleural fibrosis and adhesion by causing an inflammatory response and fibroblast proliferation, leading to symphysis of the pleural layers.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM TETRADECYL SULFATE and TALC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM TETRADECYL SULFATE is: 1% to 3% solution, 0.1-0.5 m L per injection, intravenous, as needed for sclerotherapy; maximum 10 m L per session.. The standard adult dose of TALC is: Intrapleural administration: 5 g mixed with 250 m L normal saline instilled via chest tube, followed by clamping for 1 hour then drainage.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM TETRADECYL SULFATE and TALC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM TETRADECYL SULFATE is classified as Category C. Sodium tetradecyl sulfate (STS) is a sclerosing agent with no known teratogenic effects in humans. Animal studies are limited. Use is generally avoided during pregnancy due to lack. TALC is classified as Category C. No known teratogenic risk; talc is not absorbed systemically when applied topically or used perineally. No fetal harm reported in any trimester.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.